{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"0.6","value":"2.5"},{"groupId":"OG001","spread":"0.6","value":"2.5"},{"groupId":"OG002","spread":"0.5","value":"2.5"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"1278"},{"groupId":"OG001","value":"1015"},{"groupId":"OG002","value":"263"}],"units":"Participants"}],"description":"Objective 3: To determine the extent to which the primary and secondary prophylaxis of FN in cancer patients is in congruence with the EORTC best practice guidelines and dosing recommendations, and whether this is associated with better outcomes.\n\nThe GCS is computed at the patient level as an overall grade of how congruent actual GCSF treatment is to recommended treatment. The GCS is computed as follows and scores range from 0 to 3: GCS = Σ(CRS + mean GIS over all cycles + GPS), with higher scores indicating higher congruence.\n\nCRS: Chemotherapy Risk Score (0 or 1 with 1 best); FN: febrile neutropenia; GCSF: granulocyte colony-stimulating factor; GIS=GCSF Initiation Score (0 to 1 with 1 best); GPS=GCSF persistence score (0 to 1 with 1 best);","dispersionType":"Standard Deviation","groups":[{"description":"Cancer patients treated with chemotherapy and who are prescribed commercially available filgrastim biosimilar for primary or secondary prophylaxis for FN.","id":"OG000","title":"EP2006 - All Patients"},{"description":"Cancer patients (Solid tumor) treated with chemotherapy and who are prescribed commercially available filgrastim biosimilar for primary or secondary prophylaxis for FN.","id":"OG001","title":"EP2006 - Solid Tumor"},{"description":"Cancer patients (Hematological tumor) treated with chemotherapy and who are prescribed commercially available filgrastim biosimilar for primary or secondary prophylaxis for FN.","id":"OG002","title":"EP2006 - Hematological Tumor"}],"paramType":"MEAN","populationDescription":"Evaluable sample with GCSF congruence score by tumor type","reportingStatus":"POSTED","timeFrame":"All cycles. Patients were evaluated at the enrollment cycle and then re-evaluated at each cycle for a maximum total of 6 cycles; however, the scheduling of these evaluations was left to the discretion of the physician, mean duration of study for 105 days","title":"GCSF Congruence Score (GCS)","type":"PRIMARY","unitOfMeasure":"scores on a scale"}